Denali Therapeutics
DNLI
DNLI
239 hedge funds and large institutions have $1.97B invested in Denali Therapeutics in 2025 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 90 increasing their positions, 67 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
4% more funds holding
Funds holding: 230 → 239 (+9)
2% more capital invested
Capital invested by funds: $1.93B → $1.97B (+$42.4M)
2.04% less ownership
Funds ownership: 94.71% → 92.67% (-2%)
Holders
239
Holding in Top 10
3
Calls
$3M
Puts
$1.57M
Top Buyers
| 1 | +$39.7M | |
| 2 | +$34.7M | |
| 3 | +$15.4M | |
| 4 |
SC
Stempoint Capital
New York
|
+$14.9M |
| 5 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
+$14.5M |
Top Sellers
| 1 | -$81.4M | |
| 2 | -$29.2M | |
| 3 | -$17.4M | |
| 4 |
UBS AM
Chicago,
Illinois
|
-$11.6M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$8.98M |
